Affiance Financial LLC Has $497,000 Stock Holdings in InspireMD, Inc. (NYSE:NSPR)

Affiance Financial LLC boosted its holdings in shares of InspireMD, Inc. (NYSE:NSPR) by 2.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 189,122 shares of the company’s stock after buying an additional 5,376 shares during the quarter. Affiance Financial LLC’s holdings in InspireMD were worth $497,000 at the end of the most recent quarter.

Separately, Parkman Healthcare Partners LLC bought a new position in InspireMD during the third quarter worth about $279,000. Institutional investors own 44.78% of the company’s stock.

InspireMD Trading Down 2.1 %

NYSE:NSPR opened at $2.83 on Friday. InspireMD, Inc. has a one year low of $1.81 and a one year high of $3.42. The firm’s 50 day simple moving average is $2.83 and its 200 day simple moving average is $2.73.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same period in the prior year, the business earned ($0.15) EPS. As a group, sell-side analysts expect that InspireMD, Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

NSPR has been the subject of several research reports. StockNews.com began coverage on shares of InspireMD in a research report on Tuesday, January 21st. They set a “sell” rating for the company. Lake Street Capital initiated coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price objective for the company.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.